Literature DB >> 2961004

Altered phosphate metabolism in myocardial infarction: P-31 MR spectroscopy.

P A Bottomley1, R J Herfkens, L S Smith, T M Bashore.   

Abstract

The high-energy myocardial phosphate metabolism of four patients with acute anterior myocardial infarction after coronary angioplasty and drug therapy was evaluated with cardiac-gated phosphorus magnetic resonance (MR) depth-resolved surface coil spectroscopy (DRESS) 5-9 days after the onset of symptoms. Significant reductions (about threefold) in the phosphocreatine (PCr) to inorganic phosphate (Pi) ratio and elevations in the Pi to adenosine triphosphate (ATP) ratio were observed in endocardially or transmurally derived MR spectra when compared with values from epicardially displaced spectra and values from seven healthy volunteers (P less than .05). High-energy phosphate metabolites and Pi ratios did not vary significantly during the cardiac cycle in healthy volunteers. However, contamination of Pi resonances by phosphomonoester components, including blood 2,3-diphosphoglycerate, precluded accurate spectral quantification of Pi and pH. The results indicate that localized P-31 MR spectroscopy may be used to directly assess cellular energy reserve in clinical myocardial infarction and to evaluate metabolic response to interventions.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2961004     DOI: 10.1148/radiology.165.3.2961004

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  13 in total

Review 1.  Assessing tissue metabolism by phosphorous-31 magnetic resonance spectroscopy and imaging: a methodology review.

Authors:  Yuchi Liu; Yuning Gu; Xin Yu
Journal:  Quant Imaging Med Surg       Date:  2017-12

Review 2.  Nuclear magnetic resonance in clinical pharmacology and measurement of therapeutic response.

Authors:  W H Aellig
Journal:  Br J Clin Pharmacol       Date:  1990-02       Impact factor: 4.335

3.  Cardiac metabolism during exercise in healthy volunteers measured by 31P magnetic resonance spectroscopy.

Authors:  M A Conway; J D Bristow; M J Blackledge; B Rajagopalan; G K Radda
Journal:  Br Heart J       Date:  1991-01

Review 4.  Complementarity of magnetic resonance spectroscopy, positron emission tomography and single photon emission tomography for the in vivo investigation of human cardiac metabolism and neurotransmission.

Authors:  A Syrota; P Jehenson
Journal:  Eur J Nucl Med       Date:  1991

5.  Altered creatine kinase adenosine triphosphate kinetics in failing hypertrophied human myocardium.

Authors:  Craig S Smith; Paul A Bottomley; Steven P Schulman; Gary Gerstenblith; Robert G Weiss
Journal:  Circulation       Date:  2006-09-04       Impact factor: 29.690

Review 6.  Cardiac metabolism: a technical spectrum of modalities including positron emission tomography, single-photon emission computed tomography, and magnetic resonance spectroscopy.

Authors:  R Valkema; B L van Eck-Smit; E E van der Wall
Journal:  J Nucl Cardiol       Date:  1994 Nov-Dec       Impact factor: 5.952

Review 7.  Assessment of residual viability in patients with myocardial infarction using magnetic resonance techniques.

Authors:  U Sechtem; E Voth; F Baer; C Schneider; P Theissen; H Schicha
Journal:  Int J Card Imaging       Date:  1993

8.  Quantification of human high-energy phosphate metabolite concentrations at 3 T with partial volume and sensitivity corrections.

Authors:  Abdel-Monem M El-Sharkawy; Refaat E Gabr; Michael Schär; Robert G Weiss; Paul A Bottomley
Journal:  NMR Biomed       Date:  2013-06-03       Impact factor: 4.044

9.  Reduced myocardial creatine kinase flux in human myocardial infarction: an in vivo phosphorus magnetic resonance spectroscopy study.

Authors:  Paul A Bottomley; Katherine C Wu; Gary Gerstenblith; Steven P Schulman; Angela Steinberg; Robert G Weiss
Journal:  Circulation       Date:  2009-03-30       Impact factor: 29.690

10.  Methodological advances in cardiac 31P-MR spectroscopy.

Authors:  M von Kienlin
Journal:  MAGMA       Date:  2000-11       Impact factor: 2.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.